What's Happening?
Prelude Growth Partners has invested $20 million in OneSkin, a biotech-driven skin longevity brand. Founded by female PhD scientists, OneSkin focuses on extending 'skinspan,' the period during which skin remains healthy and functional. The investment reflects Prelude Growth's confidence in OneSkin's mission and marks a significant milestone for the brand's growth. Carolina Reis Oliveira, PhD, Co-Founder and CEO of OneSkin, expressed pride in the partnership, highlighting Prelude Growth's expertise in building modern consumer brands. OneSkin's approach targets senescent cells, which contribute to aging and inflammation, using its proprietary peptide, OS-01, to reduce these cells and promote youthful skin.
AD
Why It's Important?
This investment underscores the growing interest in longevity science within the beauty industry. By focusing on the underlying mechanisms of aging, OneSkin aims to revolutionize skincare, potentially setting new standards for anti-aging products. The partnership with Prelude Growth Partners provides OneSkin with resources to expand its reach and influence, potentially benefiting consumers seeking scientifically-backed skincare solutions. The investment also highlights the increasing role of biotech in consumer products, suggesting a shift towards more science-driven approaches in the beauty sector.
What's Next?
With Prelude Growth Partners' support, OneSkin is poised to enhance its market presence and further develop its product offerings. The company may leverage this investment to expand research and development, potentially introducing new products that align with its longevity-focused mission. As OneSkin continues to grow, it may attract more attention from consumers and industry stakeholders interested in innovative skincare solutions. The partnership could also inspire other beauty brands to explore scientific approaches to skincare, potentially leading to more collaborations between biotech firms and consumer brands.
